Arm Stock Falls After HSBC Downgrade, Citing Limited Near-Term AI Upside 
Richemont Q1 Sales Beat Forecast as Cartier Demand Drives Strong Growth 
DBS Targets S$1 Trillion Wealth AUM by 2030 Amid Asia Wealth Boom 
Stripe, Advent Offer $53 Billion Deal to Acquire PayPal: Reuters 
NY Times Challenges Trump Administration Subpoenas Over Air Force One Report 
DeepSeek Eyes China IPO as AI Startup Seeks $71 Billion Valuation in New Funding Round 
Taiwan Mangoes Head to Europe as Premium Fruit Exports Expand 
BHP Q4 Iron Ore Output Rebounds as Copper Prices Boost Revenue 
Hyundai Takes Full Control of Boston Dynamics to Accelerate Humanoid Robot and AI Strategy 
Sodexo Unveils Shift & Grow 2030 Strategy, Targets Over 5% Revenue Growth by Fiscal 2030 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
Apple Intelligence China Approval Lifts Alibaba and Baidu Shares 
Volkswagen Launches €28,000 ID. Cross EV as Europe’s Electric Vehicle Demand Accelerates 
United Airlines Beats Q2 Earnings, Raises 2026 Profit Outlook Despite Higher Fuel Costs 
Rio Tinto Reports Strong Q2 Iron Ore Sales, Maintains 2026 Production Outlook 
SpaceX Stock Falls Below IPO Price as Investors Weigh Losses and Lockup Expiry 
ASML Raises 2026 Outlook as AI Chip Demand Lifts Q2 Earnings 
NEW YORK, Jan. 29, 2016 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased HeartWare International, Inc. (Nasdaq:HTWR) securities between June 10, 2014 and January 11, 2016.
Click here to learn about the case: http://docs.wongesq.com/HTWR-Info-Request-Form-1018. There is no cost or obligation to you.
The complaint alleges that during the Class Period, HeartWare and certain of its senior executives made false and misleading statements and omitted material information. In particular, it is alleged that after the U.S. Food and Drug Administration issued a Warning Letter identifying numerous manufacturing and other regulatory failures at the Company’s sole manufacturing facility, Defendants falsely assured investors that the Company had addressed those problems, and that these concerns therefore posed no risk to the clinical trials or timely approval of MVAD, a pump that HeartWare is developing.
Following a series of disclosures regarding adverse effects in certain clinical trial patients, shares of HeartWare have declined from a close of $87.73 per share on June 25, 2014, to a close of just $34.50 per share on January 22, 2016.
If you suffered a loss in HeartWare you have until March 22, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://docs.wongesq.com/HTWR-Info-Request-Form-1018.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigation involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
